Prof. Nadia Harbeck
Head of Breast Center, Oncological Therapy and Breast Clinical Trials Unit, University of München, Germany
Nadia Harbeck, MD, Ph.D., is the head of the Breast Center, Oncological Therapy and Breast Clinical Trials Unit. She holds the chair for Conservative Oncology at the Department of Obstetrics & Gynecology (Hospitals Grosshadern and Maistrasse-Innenstadt), The University of Munich (Ludwig-Maximilians-Universitӓt München [LMU]), Germany.
From 2009-2011, she was head of the Breast Center at the University of Cologne, Germany. Until 2009, she was an Associate Professor and Head of Conservative Senology at the Technical University of Munich. She started her specialist training in 1990 and obtained her specialist degree (Obstetrics & Gynecology) in 1998. In 1989, she received her medical degree
from the University of Munich (LMU).
Professor Harbeck is a member of the expert panel issuing the yearly updated evidence-based Working Group for Gynecologic Oncology (AGO) Guidelines for breast cancer therapy in Germany (www.ago-online.de). In addition, she is an executive board member of the European Organisation for Research and Treatment of Cancer (EORTC), a steering committee member of the EORTC Pathobiology Group and numerous other professional organizations.
Professor Harbeck is the Scientific Director of the West German Study Group (WSG, a BIG member) focuses on early breast cancer trials with a strong translational research program. She is the principal investigator or steering committee member of numerous national and international clinical breast cancer trials, with a recent focus on tests using novel targeted compounds. She is a member of the Trans HERA committee and co-chair of the Trans ALTTO committee. Her translational research focuses on prognostic and predictive factors in breast cancer and other solid tumors.
Professor Harbeck has authored more than 280 papers in peer-reviewed journals (cumulative impact factor ~ 1200) and is the coordinating editor-in-chief of Breast Care. For her clinical translational research, she has received numerous awards, including the 2012 Claudia von
Schilling Award, the 2002 AGO Schmidt-Matthiesen Award, 2001 American Association for Cancer Research (AACR) Research Award, and the 2001 American Society of Clinical Oncology (ASCO) Fellowship Merit Award for the highest-ranking abstract submitted.
Professor Harbeck was invited to give a keynote lecture at the Danish Cancer Society in 2010, the opening speech at IBCM-2 2009, a keynote lecture at the 2008 Congress of the German Cancer Society (DKG), and the Emmanuel van der Schueren Lecture at the 2008 European Breast Cancer Conference (EBCC-6). In 2011, Professor Harbeck co-chaired the 3rd IMPAKT meeting and the EORTC-NCI-ASCO Meeting on Molecular Markers. She is also a faculty and panel member of the International Conference on Breast Cancer in Young Women (1st BCY 2012) and of the International Consensus on Advanced Breast Cancer (ABC 2011 & 2013).
